Massive umbrella review maps the strength of evidence for cannabis risks and benefits
An umbrella review of 101 meta-analyses found convincing evidence linking cannabis to psychosis and car crashes, moderate evidence for some therapeutic benefits, but weak evidence for most other claimed associations.
Quick Facts
What This Study Found
Of hundreds of reported associations, only a handful met the threshold for convincing or highly suggestive evidence. Harmful associations (psychosis, motor vehicle accidents, low birth weight) had stronger evidence than most therapeutic claims.
Key Numbers
101 meta-analyses reviewed. Convincing harmful associations: psychosis incidence, motor vehicle accidents, low birth weight. Most therapeutic associations graded as low or very low certainty by GRADE.
How They Did This
Umbrella review of systematic reviews with meta-analyses from observational studies and RCTs. Credibility graded as convincing, highly suggestive, suggestive, weak, or not significant. RCT evidence graded using GRADE. Quality assessed with AMSTAR 2.
Why This Research Matters
The cannabis literature is vast and contradictory. This umbrella review cuts through the noise by systematically rating the credibility of every major claimed risk and benefit, giving the clearest available picture of what the evidence actually supports.
The Bigger Picture
Both cannabis advocates and opponents tend to cherry-pick studies. This comprehensive evidence map shows the reality is nuanced: some risks are well-established, some benefits are real but modest, and most claims in either direction rest on weak evidence.
What This Study Doesn't Tell Us
Umbrella reviews are only as good as the underlying meta-analyses, many of which had methodological weaknesses. Rapidly evolving cannabis products (high-potency, concentrates, edibles) may not be captured in older studies. Publication bias may affect underlying reviews.
Questions This Raises
- ?How do the risk-benefit profiles differ across specific cannabinoid formulations and delivery methods?
- ?Will future high-quality RCTs shift any of the current evidence grades substantially?
Trust & Context
- Key Stat:
- 101 meta-analyses reviewed; few associations reached convincing evidence level
- Evidence Grade:
- Umbrella review is the highest level of evidence synthesis. Findings are limited by quality of underlying meta-analyses, but the methodology is rigorous.
- Study Age:
- Published 2022. Literature search through February 2022.
- Original Title:
- Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
- Published In:
- BMJ (Clinical research ed.), 382, e072348 (2023)
- Authors:
- Solmi, Marco(11), De Toffol, Marco, Kim, Jong Yeob, Choi, Min Je, Stubbs, Brendon, Thompson, Trevor, Firth, Joseph, Miola, Alessandro, Croatto, Giovanni, Baggio, Francesca, Michelon, Silvia, Ballan, Luca, Gerdle, Björn, Monaco, Francesco, Simonato, Pierluigi, Scocco, Paolo, Ricca, Valdo, Castellini, Giovanni, Fornaro, Michele, Murru, Andrea, Vieta, Eduard, Fusar-Poli, Paolo, Barbui, Corrado, Ioannidis, John P A, Carvalho, Andrè F, Radua, Joaquim, Correll, Christoph U, Cortese, Samuele, Murray, Robin M, Castle, David, Shin, Jae Il, Dragioti, Elena
- Database ID:
- RTHC-04952
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What risks of cannabis have the strongest evidence?
The umbrella review found convincing evidence linking cannabis use to increased risk of psychosis, motor vehicle accidents, and low birth weight in offspring. These associations met the highest credibility threshold across multiple meta-analyses.
What about medical benefits?
Some therapeutic benefits had moderate evidence, particularly for chronic pain and chemotherapy-related nausea. However, most claimed benefits were graded as low or very low certainty under the GRADE framework, meaning the evidence is not as strong as often assumed.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBD-oil-quality-guide
- CBT-cannabis-recovery
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cannabis-relapse-cycle-pattern
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- cold-turkey-vs-taper-quit-weed
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- how-to-quit-weed
- journaling-weed-withdrawal
- marijuana-anonymous-SMART-recovery-compare
- medical-benefits-of-cannabis
- meditation-mindfulness-weed-withdrawal
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-before-surgery
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- seniors-older-adults-cannabis-risks-medications
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-breastfeeding-THC-breast-milk
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-04952APA
Solmi, Marco; De Toffol, Marco; Kim, Jong Yeob; Choi, Min Je; Stubbs, Brendon; Thompson, Trevor; Firth, Joseph; Miola, Alessandro; Croatto, Giovanni; Baggio, Francesca; Michelon, Silvia; Ballan, Luca; Gerdle, Björn; Monaco, Francesco; Simonato, Pierluigi; Scocco, Paolo; Ricca, Valdo; Castellini, Giovanni; Fornaro, Michele; Murru, Andrea; Vieta, Eduard; Fusar-Poli, Paolo; Barbui, Corrado; Ioannidis, John P A; Carvalho, Andrè F; Radua, Joaquim; Correll, Christoph U; Cortese, Samuele; Murray, Robin M; Castle, David; Shin, Jae Il; Dragioti, Elena. (2023). Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.. BMJ (Clinical research ed.), 382, e072348. https://doi.org/10.1136/bmj-2022-072348
MLA
Solmi, Marco, et al. "Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.." BMJ (Clinical research ed.), 2023. https://doi.org/10.1136/bmj-2022-072348
RethinkTHC
RethinkTHC Research Database. "Balancing risks and benefits of cannabis use: umbrella revie..." RTHC-04952. Retrieved from https://rethinkthc.com/research/solmi-2023-balancing-risks-and-benefits
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.